ConductScience.org, home

Paper25634992

Characterization of Escherichia coli NDM isolates with decreased susceptibility to aztreonam/avibactam: role of a novel insertion in PBP3.

Alm RA and 2 others. J Antimicrob Chemother, 2015. Cited by 167 papers, by iCite.

Cite this record

ConductScience Library. Characterization of Escherichia coli NDM isolates with decreased susceptibility to aztreonam/avibactam: role of a novel insertion in PBP3. Papers, record 25634992. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/25634992

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Characterization of Escherichia coli NDM isolates with decreased susceptibility to aztreonam/avibactam: role of a novel insertion in PBP3.
PubMed
Journal
J Antimicrob Chemother
PubMed
Year
2015
PubMed
Publication types
Journal Article, Research Support, Non-U.S. Gov't
PubMed
Citations, by iCite
167
iCite
Relative citation ratio, by iCite
7.25
iCite
Revised in PubMed
2022-04-08
PubMed

Authors3

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Alm RARichard A
2Johnstone MRMichele R
3Lahiri SDSushmita D

Source PubMed

Download CSV of authors

Topics14

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Anti-Bacterial AgentsMajor topic
Azabicyclo CompoundsMajor topic
AztreonamMajor topic
Escherichia coliMajor topic
Penicillin-Binding ProteinsMajor topic
beta-Lactam ResistanceMajor topic
beta-LactamasesMajor topic
Computational Biology
Escherichia coli Infections
Genome, Bacterial
Humans
Microbial Sensitivity Tests
Mutagenesis, Insertional
Sequence Analysis, DNA

Source PubMed

Download CSV of topics

Cited by116

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 167 citations.

PMIDTitleJournalYearIn PapersSource
42932391L-Histidine resensitizes multidrug-resistant bacteria to carbapenems by inhibiting New Delhi metallo-β-lactamase activity.PLoS Pathog2026https://conductscience.org/library/papers/42932391PubMed
42747332Escherichia coli with penicillin-binding protein 3 insertions: implications for newer β-lactam/β-lactamase inhibitor combinations.Antimicrob Agents Chemother2026https://conductscience.org/library/papers/42747332PubMed
42650674Clinical Emergence and Genomic Characterization of Aztreonam-Avibactam-Resistant Escherichia coli ST410 Isolates in China.Antibiotics (Basel)2026https://conductscience.org/library/papers/42650674PubMed
42593110Outbreak of aztreonam-avibactam-resistant NDM-5-producing Escherichia coli isolates in a hospital of Paris.Microbiol Spectr2026https://conductscience.org/library/papers/42593110PubMed
42549896In vitro susceptibility testing of aztreonam-avibactam against predominantly NDM-producing Enterobacterales in Peru.Microbiol Spectr2026https://conductscience.org/library/papers/42549896PubMed
42379811In vitro activity of aztreonam-avibactam and comparators against Enterobacterales isolated from bloodstream infections: ATLAS/ surveillance, 2021-2022.Microbiol Spectr2026https://conductscience.org/library/papers/42379811PubMed
42267316Carbapenemases: epidemiology, detection and management in a changing global landscape.JAC Antimicrob Resist2026https://conductscience.org/library/papers/42267316PubMed
42103067Emergence of Klebsiella pneumoniae Carbapenemase-Producing K. pneumoniae with Penicillin-Binding Protein 3 Insertions, Taiwan, 2021.Emerg Infect Dis2026https://conductscience.org/library/papers/42103067PubMed
42041376Clinically Significant Carbapenemases in Gram-Negative Pathogens: Molecular Diversity and Advances in β-Lactamase Inhibitor Therapy.Antibiotics (Basel)2026https://conductscience.org/library/papers/42041376PubMed
41971938Successful treatment of carbapenem-resistant Acinetobacter baumannii and Enterobacterales coinfection with sulbactam-durlobactam combined with aztreonam: a case report.AME Case Rep2026https://conductscience.org/library/papers/41971938PubMed
41940810Case Commentary: When one target is not enough-PBP3 insertions and target redundancy in Escherichia coli.Antimicrob Agents Chemother2026https://conductscience.org/library/papers/41940810PubMed
41870042Clinical and genomic determinants associated with emergent ceftazidime-avibactam plus aztreonam non-susceptibility in ceftazidime-avibactam resistant Escherichia coli.Antimicrob Agents Chemother2026https://conductscience.org/library/papers/41870042PubMed
41606461Genome-wide screening of antibiotic survival genes in Escherichia coli MG1655.BMC Microbiol2026https://conductscience.org/library/papers/41606461PubMed
41577890Aztreonam plus ceftazidime/avibactam broth disk elution test: failure to detect Escherichia coli with PBP-3 insertions.Eur J Clin Microbiol Infect Dis2026https://conductscience.org/library/papers/41577890PubMed
41334908APC24-7, a covalent combination of boronic acid and chelator moieties, restores β-lactam efficiency against metallo-β-lactamase-producers.mSphere2025https://conductscience.org/library/papers/41334908PubMed
41258612Aztreonam-Avibactam: A Review in the Treatment of Serious Bacterial Infections Caused by Aerobic Gram-Negative Organisms.Drugs2026https://conductscience.org/library/papers/41258612PubMed
41140275Antimicrobial resistance among Gram-negative agents of bacteraemia in the UK and Ireland: trends from 2001 to 2019.J Antimicrob Chemother2025https://conductscience.org/library/papers/41140275PubMed
41071106In vitro evolution of durlobactam resistance in NDM-producing Escherichia coli due to a single mutation in mrdA encoding penicillin-binding protein 2.Antimicrob Agents Chemother2025https://conductscience.org/library/papers/41071106PubMed
40756421In vivo evolution of ceftazidime-avibactam resistance in bla OXA-244-positive E. coli potentially linked to PBP3 insertion and mutations in acrB and PBP2.JAC Antimicrob Resist2025https://conductscience.org/library/papers/40756421PubMed
40711423
Broad spectrum of β-lactamase coverage and potent antimicrobial activity of xeruborbactam in combination with meropenem against carbapenemase-producing Enterobacterales, including strains resistant to new β-lactam/β-lactamase inhibitor combinations.
Antimicrob Agents Chemother2025https://conductscience.org/library/papers/40711423PubMed

See all 116 cited byDownload CSV of cited by

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • References
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/25634992

GET https://conductscience.org/api/papers/v1/25634992/cited_by?page=2